Papilledema and idiopathic intracranial hypertension

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Papilledema is one of the most concerning physical examination findings in neurology: it has a broad differential diagnosis of intracranial (and occasionally spinal) pathology associated with increased intracranial pressure. Papilledema impairs axoplasmic flow within the optic nerves and compresses the optic nerves externally; it may lead to profound visual loss. Thus, detection of papilledema and assessment of visual function are essential to patient management. This article reviews the treatment of papilledema-related visual loss in pseudotumor cerebri syndrome, one of the most common causes of papilledema encountered by neurologists.

RECENT FINDINGS: Results from the Idiopathic Intracranial Hypertension Trial (IIHTT), the first randomized, double-masked, placebo-controlled trial for the treatment of patients with mild visual loss from idiopathic intracranial hypertension, were published in April 2014. The IIHTT provides the first evidence-based treatment recommendations, showing the benefit of acetazolamide and weight loss for improving visual status in patients with mild visual field loss from idiopathic intracranial hypertension.

SUMMARY: A detailed ophthalmic examination, including perimetry, is critical to the evaluation, treatment, and assessment of treatment response in patients with papilledema.

Original languageEnglish (US)
Pages (from-to)857-876
Number of pages20
JournalContinuum (Minneapolis, Minn.)
Volume20
Issue number4 Neuroophthalmology
DOIs
StatePublished - Aug 1 2014

Fingerprint

Pseudotumor Cerebri
Papilledema
Optic Nerve
Therapeutics
Visual Field Tests
Acetazolamide
Axonal Transport
Intracranial Pressure
Neurology
Visual Fields
Physical Examination
Weight Loss
Differential Diagnosis
Placebos
Pathology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Papilledema and idiopathic intracranial hypertension. / Friedman, Deborah I.

In: Continuum (Minneapolis, Minn.), Vol. 20, No. 4 Neuroophthalmology, 01.08.2014, p. 857-876.

Research output: Contribution to journalArticle

@article{dd58ec5b4fd5448b8e622b633b2541b1,
title = "Papilledema and idiopathic intracranial hypertension",
abstract = "PURPOSE OF REVIEW: Papilledema is one of the most concerning physical examination findings in neurology: it has a broad differential diagnosis of intracranial (and occasionally spinal) pathology associated with increased intracranial pressure. Papilledema impairs axoplasmic flow within the optic nerves and compresses the optic nerves externally; it may lead to profound visual loss. Thus, detection of papilledema and assessment of visual function are essential to patient management. This article reviews the treatment of papilledema-related visual loss in pseudotumor cerebri syndrome, one of the most common causes of papilledema encountered by neurologists.RECENT FINDINGS: Results from the Idiopathic Intracranial Hypertension Trial (IIHTT), the first randomized, double-masked, placebo-controlled trial for the treatment of patients with mild visual loss from idiopathic intracranial hypertension, were published in April 2014. The IIHTT provides the first evidence-based treatment recommendations, showing the benefit of acetazolamide and weight loss for improving visual status in patients with mild visual field loss from idiopathic intracranial hypertension.SUMMARY: A detailed ophthalmic examination, including perimetry, is critical to the evaluation, treatment, and assessment of treatment response in patients with papilledema.",
author = "Friedman, {Deborah I.}",
year = "2014",
month = "8",
day = "1",
doi = "10.1212/01.CON.0000453314.75261.66",
language = "English (US)",
volume = "20",
pages = "857--876",
journal = "CONTINUUM Lifelong Learning in Neurology",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "4 Neuroophthalmology",

}

TY - JOUR

T1 - Papilledema and idiopathic intracranial hypertension

AU - Friedman, Deborah I.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - PURPOSE OF REVIEW: Papilledema is one of the most concerning physical examination findings in neurology: it has a broad differential diagnosis of intracranial (and occasionally spinal) pathology associated with increased intracranial pressure. Papilledema impairs axoplasmic flow within the optic nerves and compresses the optic nerves externally; it may lead to profound visual loss. Thus, detection of papilledema and assessment of visual function are essential to patient management. This article reviews the treatment of papilledema-related visual loss in pseudotumor cerebri syndrome, one of the most common causes of papilledema encountered by neurologists.RECENT FINDINGS: Results from the Idiopathic Intracranial Hypertension Trial (IIHTT), the first randomized, double-masked, placebo-controlled trial for the treatment of patients with mild visual loss from idiopathic intracranial hypertension, were published in April 2014. The IIHTT provides the first evidence-based treatment recommendations, showing the benefit of acetazolamide and weight loss for improving visual status in patients with mild visual field loss from idiopathic intracranial hypertension.SUMMARY: A detailed ophthalmic examination, including perimetry, is critical to the evaluation, treatment, and assessment of treatment response in patients with papilledema.

AB - PURPOSE OF REVIEW: Papilledema is one of the most concerning physical examination findings in neurology: it has a broad differential diagnosis of intracranial (and occasionally spinal) pathology associated with increased intracranial pressure. Papilledema impairs axoplasmic flow within the optic nerves and compresses the optic nerves externally; it may lead to profound visual loss. Thus, detection of papilledema and assessment of visual function are essential to patient management. This article reviews the treatment of papilledema-related visual loss in pseudotumor cerebri syndrome, one of the most common causes of papilledema encountered by neurologists.RECENT FINDINGS: Results from the Idiopathic Intracranial Hypertension Trial (IIHTT), the first randomized, double-masked, placebo-controlled trial for the treatment of patients with mild visual loss from idiopathic intracranial hypertension, were published in April 2014. The IIHTT provides the first evidence-based treatment recommendations, showing the benefit of acetazolamide and weight loss for improving visual status in patients with mild visual field loss from idiopathic intracranial hypertension.SUMMARY: A detailed ophthalmic examination, including perimetry, is critical to the evaluation, treatment, and assessment of treatment response in patients with papilledema.

UR - http://www.scopus.com/inward/record.url?scp=84927170072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927170072&partnerID=8YFLogxK

U2 - 10.1212/01.CON.0000453314.75261.66

DO - 10.1212/01.CON.0000453314.75261.66

M3 - Article

C2 - 25099098

AN - SCOPUS:84905903749

VL - 20

SP - 857

EP - 876

JO - CONTINUUM Lifelong Learning in Neurology

JF - CONTINUUM Lifelong Learning in Neurology

SN - 1080-2371

IS - 4 Neuroophthalmology

ER -